Comparing high versus low dose of nebulised salbutamol in acute adult asthmatics presenting to the Emergency Department.

Not Applicable

• Conditions: Asthma; Emergency medicine - Other emergency care; Respiratory - Asthma

• Registration Number: ACTRN12618000400268
• Lead Sponsor: Medical Research Institute of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-20
• Study Completion: 2021-02-14
• Last Update Posted: 3 October 2023

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

•Doctor diagnosis of asthma
•Age 18 to 65 years
•Presentation to ED with a severe asthma exacerbation
•PEF < 50% of predicted
•Concomitant asthma medication may include: none, ICS, ICS/LABA, theophylline, LTRA, oral steroids, sodium cromoglycate, nedocromil sodium

Exclusion Criteria

•Inability to perform spirometry
•Requirement for Non-invasive ventilation (NIV) or intubation at presentation
•Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FEV1 using bedside handheld spirometry. [ At 60minutes post treatment protocol commencement, ]

Secondary Outcome Measures

Name	Time	Method
FEV1 using bedside handheld spirometry.[ At 20 and 40 minutes post treatment protocol commencement];Total dose of salbutamol administered at 120minutes post commencement of treatment protocol. This will be recorded by the attending clinician on the trial proforma. [ 120minutes post commencement of treatment protocol];Length of stay in ED. This will be monitored by the investigator. [ When patient leaves the Emergency Department for another inpatient location or discharge from hospital. ];Treatment failure defined as the need for non-invasive or invasive ventilation and IV salbutamol. This will be recorded by the investigator. [ 60minutes post commencement of treatment protocol];Adverse events: symptoms mirroring salbutamol toxicity, such as tremor, anxiety, uncharacteristic tachycardia or tachypnoea. These measures will be identified by the treating clinician and recorded by the investigator. [ At 60minutes after commencement of the treatment protocol. ]